| Autor: |
Boss, Susan M., Huster, William J., Neild, Julie A., Glant, Michael D., Eisenhut, Carol C., Draper, Michael W., Boss, S M, Huster, W J, Neild, J A, Glant, M D, Eisenhut, C C, Draper, M W |
| Předmět: |
|
| Zdroj: |
American Journal of Obstetrics & Gynecology; Dec97, Vol. 177 Issue 6, p1458-1464, 7p, 4 Charts |
| Abstrakt: |
Objective: We evaluated subtle endometrial morphologic changes in postmenopausal women assigned to placebo, raloxifene hydrochloride 200 or 600 mg/day, or conjugated estrogens (Premarin 0.625 mg/day) according to a new estrogenicity scoring system. Raloxifene, a new selective estrogen receptor modulator, was not expected to stimulate the endometrium.Study Design: Baseline and end point endometrial biopsies were performed during this double-blind, placebo-controlled 8-week study. A scoring system that was based on standard glandular and stromal morphologic criteria was used to quantitate estrogen-induced effects. Baseline, end point, and baseline-to-end point changes were analyzed for treatment differences.Results: Treatment groups were similar at baseline with most women showing no estrogenic effects. At end point, statistically significant moderate and marked estrogenic effects were noted in 77% of estrogen-treated women versus 15% of placebo-treated women versus 0% of raloxifene-treated women.Conclusions: As expected, estrogen treatment stimulated postmenopausal endometrium. In contrast, raloxifene did not induce histopathologic evidence of endometrial stimulation in healthy postmenopausal women. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect